Related Experiment Videos
Calcium channel blockers and pain therapy.
1Glaxo Wellcome Research and Development, Department of Medicinal Chemistry 1, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom. BC5958@glaxowellcome.co.uk
Current Review of Pain
|November 4, 2000
Summary
This review covers recent advances in N-type calcium channel blockers for pain relief. It discusses clinical progress with Ziconotide and new strategies for developing oral, small molecule pain medications.
Area of Science:
- Pharmacology
- Drug Development
- Pain Management
Background:
- N-type calcium channels are key targets for analgesia.
- Ziconotide (SNX-111) shows clinical promise but has limitations.
- Need for improved analgesic agents with better delivery and fewer side effects.
Purpose of the Study:
- To review recent advancements in N-type calcium channel blockers for pain.
- To highlight clinical progress of Ziconotide.
- To explore novel strategies for developing orally active small molecule modulators.
Main Methods:
- Literature review of studies published in the last two years.
- Analysis of clinical trial data for Ziconotide.
- Examination of research approaches for small molecule N-type calcium channel blockers.
Main Results:
- Ziconotide has demonstrated clinical efficacy in pain management.
- Researchers are actively pursuing orally bioavailable small molecule N-type calcium channel blockers.
- New design strategies aim to overcome Ziconotide's limitations.
Conclusions:
- N-type calcium channel blockers represent a promising class of analgesics.
- Further development is needed to optimize delivery and safety profiles.
- Orally active small molecules offer a potential alternative to existing therapies.